Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Argan (AGX) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Argan (AGX) over the last 17 years, with Q4 2025 value amounting to $306.3 million.

  • Argan's Cash & Equivalents rose 7467.68% to $306.3 million in Q4 2025 from the same period last year, while for Oct 2025 it was $306.3 million, marking a year-over-year increase of 7467.68%. This contributed to the annual value of $145.3 million for FY2025, which is 2627.44% down from last year.
  • Argan's Cash & Equivalents amounted to $306.3 million in Q4 2025, which was up 7467.68% from $177.8 million recorded in Q3 2025.
  • In the past 5 years, Argan's Cash & Equivalents ranged from a high of $451.4 million in Q3 2021 and a low of $136.1 million during Q4 2022
  • Its 5-year average for Cash & Equivalents is $241.0 million, with a median of $196.5 million in 2023.
  • As far as peak fluctuations go, Argan's Cash & Equivalents skyrocketed by 11908.73% in 2021, and later plummeted by 6824.56% in 2022.
  • Argan's Cash & Equivalents (Quarter) stood at $391.6 million in 2021, then crashed by 65.25% to $136.1 million in 2022, then skyrocketed by 36.38% to $185.6 million in 2023, then dropped by 5.51% to $175.3 million in 2024, then soared by 74.68% to $306.3 million in 2025.
  • Its Cash & Equivalents was $306.3 million in Q4 2025, compared to $177.8 million in Q3 2025 and $189.3 million in Q2 2025.